ULTRAGENYX PHARMACEUTICAL INC. Restricted Cash, Current
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Restricted Cash, Current of $9.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:RestrictedCashCurrent · last filed 2026-08-05
- 2026-06-30: Restricted Cash, Current $9.00M.
- 2026-03-31: Restricted Cash, Current $8.00M.
- 2025-12-31: Restricted Cash, Current $13.00M.
- 2025-09-30: Restricted Cash, Current $9.83M.
| Period end | Restricted Cash, Current | Restricted Cash, Current as first filed |
|---|---|---|
| 2026-06-30 | $9.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $8.00M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $13.00M 10-K · filed 2026-02-18 | |
| 2025-09-30 | $9.83M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $9.00M 10-Q · filed 2026-08-05 | $9.04M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $8.00M 10-Q · filed 2026-05-06 | $8.48M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $7.00M 10-K · filed 2026-02-18 | $6.81M 10-K · filed 2025-02-19 |
| 2024-09-30 | $6.18M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $6.17M 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $6.30M 10-Q · filed 2025-05-07 | |
| 2023-12-31 | $2.00M 10-K · filed 2026-02-18 | $2.01M 10-K · filed 2024-02-21 |
| 2023-09-30 | $1.98M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $1.70M 10-Q · filed 2024-08-02 | |
| 2023-03-31 | $1.96M 10-Q · filed 2024-05-03 | |
| 2022-12-31 | $862.00K 10-K · filed 2025-02-19 | |
| 2022-09-30 | $517.00K 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $517.00K 10-Q · filed 2023-08-04 | |
| 2022-03-31 | $217.00K 10-Q · filed 2023-05-05 | |
| 2021-12-31 | $0.00 10-K · filed 2024-02-21 | |
| 2021-09-30 | $10.00M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $10.00M 10-Q · filed 2022-07-29 | |
| 2021-03-31 | $10.69M 10-Q · filed 2022-05-06 | |
| 2020-12-31 | $10.85M 10-K · filed 2023-02-17 | |
| 2020-09-30 | $847.00K 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $847.00K 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $161.00K 10-Q · filed 2021-05-05 | |
| 2019-12-31 | $161.00K 10-K · filed 2022-02-15 | |
| 2019-09-30 | $161.00K 10-Q · filed 2020-10-27 | |
| 2019-06-30 | $161.00K 10-Q · filed 2020-07-30 | |
| 2019-03-31 | $351.00K 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $271.00K 10-K · filed 2021-02-12 | |
| 2018-09-30 | $652.00K 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $652.00K 10-Q · filed 2019-08-02 | |
| 2018-03-31 | $542.00K 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $461.00K 10-K · filed 2020-02-14 | |
| 2017-09-30 | $461.00K 10-Q · filed 2018-11-06 | |
| 2016-12-31 | $1.41M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |